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Characterization of Focal Liver Lesions
with Superparamagnetic Iron Oxide-
Enhanced MR Imaging: Value of
Distributional Phase T1-Weighted Imaging
Objective: To determine the potential value of distributional-phase T1-weight-
ed ferumoxides-enhanced magnetic resonance (MR) imaging for tissue charac-
terization of focal liver lesions.
Materials and Methods: Ferumoxides-enhanced MR imaging was performed
using a 1.5-T system in 46 patients referred for evaluation of known or suspected
hepatic malignancies. Seventy-three focal liver lesions (30 hepatocellular carci-
nomas [HCC], 12 metastases, 15 cysts, 13 hemangiomas, and three cholangio-
carcinomas) were evaluated. MR imaging included T1-weighted double-echo
gradient-echo (TR/TE: 150/4.2 and 2.1 msec), T2 -weighted gradient-echo
(TR/TE: 180/12 msec), and T2-weighted turbo spin-echo MR imaging at 1.5 T
before and after intravenous administration of ferumoxides (15 mmol/kg body
weight). Postcontrast T1-weighted imaging was performed within eight minutes of
infusion of the contrast medium (distributional phase). Both qualitative and quan-
titative analysis was performed.
Results: During the distributional phase after infusion of ferumoxides, unique
enhancement patterns of focal liver lesions were observed for hemangiomas,
metastases, and hepatocellular carcinomas. On T1-weighted GRE images
obtained during the distributional phase, hemangiomas showed a typical positive
enhancement pattern of increased signal; metastases showed ring enhance-
ment; and hepatocellar carcinomas showed slight enhancement. Quantitatively,
the signal-to-noise ratio of hemangiomas was much higher than that of other
tumors (p < .05) and was similar to that of intrahepatic vessels. This finding per-
mitted more effective differentiation between hemangiomas and other malignant
tumors.
Conclusion: T1-weighted double-echo FLASH images obtained soon after the
infusion of ferumoxides, show characteristic enhancement patterns and improved
the differentiation of focal liver lesions.
maging work-up of the liver is performed primarily to screen patients
with known primary malignancies or those at high risk, or to characterize
lesions detected with other modalities (1). Superparamagnetic iron oxides
(SPIOs), such as ferumoxide, are reticuloendothelial-specific contrast agents taken up
primarily by the Kupffer cells of the liver and used to improve the detection of focal
liver lesions at MR imaging (2 6). After SPIO administration, the liver parenchymal
signal seen at T2- and T2*-weighted imaging increases liver-to-lesion contrast and po-
tentially improves the detection of focal liver lesions (2 3). It has been shown that for
the detection of focal liver lesions, SPIO-enhanced MR imaging is substantially more
sensitive than CT or non-enhanced MR imaging, and at least as accurate as CT during
arterial portography (1, 4, 6). In previous studies of ferumoxides-enhanced MR imag-
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Iing, T2*-weighted gradient-recalled echo (GRE) and T2-
weighted turbo spin-echo (TSE) sequences were used and
are considered the preferable techniques for SPIO-en-
hanced MR imaging.
In determining an accurate treatment plan, the character-
ization of focal hepatic lesions is as important as their de-
tection. Furthermore, since up to 50% of lesions less than
15 mm in diameter may be benign, lesion characterization
is of special importance in patients with a primary hepatic
malignancy (7). Although ferumoxides-enhanced MR imag-
ing may increase the detectability of focal liver tumors,
their characterization may be problematic because their
appearance can be modified by ferumoxides (8 11). Some
reports have claimed that tissue characterization improves
with T1-weighted imaging after the administration of
SPIOs, using their R1 relaxivity (8 10, 12, 13); in those
studies, images were usually acquired one hour after feru-
moxides administration ended. However, the plasma half-
life of ferumoxides is reported to be less than 10 mins (9,
14), and to observe their T1 effect, the earlier acquisition
of images, during the distributional phase (less than 10
minutes after administration) and using a T1-weighted se-
quence with minimum echo time, may be helpful and may
provide additional information for tissue characterization
of focal liver lesions.
The purpose of this study is to assess the value of feru-
moxides-enhanced T1-weighted MR imaging performed
during the distributional phase for tissue characterization
of focal liver lesions.
MATERIALS AND METHODS
Patients
Our study population comprised 46 patients (35 men and
11 women) with a mean age of 58.5 (range, 52 72) years.
Informed consent was obtained from each. Seventy-three
lesions were detected and included 30 hepatocellular carci-
nomas (HCC) in 20 patients, 12 metastases in six, 15 cysts
in nine, 13 hemangiomas in eight, and three cholangiocar-
cinomas in three. In each subject, between one and four le-
sions were present. Two had two types of lesion and one
had three types. The lesions were 0.5 7 (mean 3.4 1.8)
cm in diameter.
Diagnosis of the various lesions was established as fol-
lows. That of HCC was based on the findings of percuta-
neous biopsy (n=7), examination of a surgical specimen
(n=3), or was on the basis of typical clinical and laboratory
findings in combination with evidence of disease progres-
sion, as depicted at follow-up imaging (n=10). Liver metas-
tases were diagnosed on the basis of histological findings in
the primary tumor and rapid progression of the lesion, as
depicted at serial follow-up imaging (n=2) or by examining
percutaneous needle biopsy specimens (n=4). Liver metas-
tases were related to the following histologically proven
primary tumors: carcinoma of the colon (n=3), stomach (n
=2), and lung (n=1). Confirmation of cholangiocarcinomas
was based on the histological findings (n=3), while heman-
giomas were diagnosed on the basis of their typical appear-
ance at triple-phase helical computed tomography and dy-
namic MR imaging performed sequentially over a five-
minute period following the injection of iodinated contrast
medium or gadolinium chelates, and the absence of growth
during a follow-up period of at least six months (15 18).
For liver cysts, diagnosis was based on established criteria,
as observed at contrast-enhanced CT, ultrasound and un-
enhanced MR imaging, and during a clinical follow-up peri-
od of at least six months (15, 16).
MR Imaging 
Images were obtained with a 1.5 T scanner (Symphony;
Siemens Medical Systems, Erlangen, Germany) using a
body phased-array coil. All patients underwent unen-
hanced and ferumoxides (Feridex I.V.; Advanced
Magnetics, Cambridge, Mass., U.S.A.)-enhanced MR imag-
ing using the following sequences: respiratory-triggered,
T2-weighted turbo spin-echo (TSE); breath-hold T2*-
weighted gradient-recalled echo (GRE); breath-hold T2-
weighted TSE; and breath-hold T1-weighted double-echo
GRE images (TE 4.2/ 2.1 msec).
For respiratory-triggered T2-weighted TSE imaging, the
following parameters were used: a TR range/effective TE
of 3500 5600/80, an echo-train length of 15, three signal
averages, and a matrix of 192 256. Those for breath-hold
T2-weighted TSE included a TR/TE of 2500/100, a flip an-
gle of 150, and a matrix of 132 256, while for breath-
hold T2*-weighted gradient-echo imaging, a TR/TE of
180/12, a flip angle of 30 , and a matrix of 132 256 were
used. One signal was acquired and two or three data acqui-
sitions were performed. Breath-hold T1-weighted double-
echo GRE images were obtained with a TR/TE 150/4.2 and
2.1, a 70 flip angle, one signal average, and a matrix of
256 132. For all sequences, imaging was performed in
the axial plane with a section thickness of 7 mm, an inter-
section gap of 3 mm, and a rectangular field of view of
24 28 30 34 cm. The phase-encoding direction was an-
terior to posterior for all sequences.
Ferumoxides was administered at 15  mol of iron per
kilogram of body weight; the suspension was diluted in
100 mL of 5% glucose solution and administered intra-
venously at a rate of approximately 4 mL/min for 25 min-
utes. Postcontrast T1-weighted MR images were obtained
not more than 10 minutes later (distributional phase), and
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obtained 10 30 minutes after the end of contrast adminis-
tration (accumulation phase).
Image Analysis
Qualitative Analysis
Two radiologists experienced in abdominal MR imaging
assessed the enhancement pattern of both precontrast and
postcontrast (ferumoxides-enhanced) MR images. They
had no knowledge of patient history or diagnosis, and
reached their conclusion by consensus. For each lesion, sig-
nal intensity relative to hepatic parenchyma was recorded
as hypo-, iso- or hyperintense. For hyperintense lesions
showing enhancement at ferumoxides-enhanced T1-
weighted imaging, the readers were asked to state whether
or not the enhancement patterns were ring-shaped.
To assess the reliability of ferumoxides-enhanced T1-
weighted imaging for the characterization of focal liver le-
sions, two radiologists who interpret MR images of the liv-
er as part of their daily clinical and research practice, and
who were blinded to the diagnosis and clinical history, re-
viewed two sets of images: a) postcontrast accumulation-
phase T2-weighted and T2*-weighted (reading set A); and
b) combined distributional-phase T1-weighted in- and op-
posed-phase and accumulation phase (reading set B). The
images were randomized and presented at two sessions,
with patient data masked. To minimize learning bias, the
review sessions were held at two-week intervals. At each,
the readers were asked to provide a diagnosis according to
previously published established criteria, and a consensus
was then reached (8 12, 14 16).
The diagnostic criteria for cyst, hemangioma, metastasis
and HCC were as follows. Lesions showing no enhance-
ment at postcontrast T1- and T2-weighted imaging were
considered to be cysts; those showing positive enhance-
ment similar to that of the intrahepatic vessels at T1-
weighted and negative enhancement at T2-weighted imag-
ing were classified as hemangiomas. Lesions in which ring
enhancement was apparent at postcontrast-T1 weighted
imaging were considered to be metastases, while those
showing slight enhancement at T1-weighted and no en-
hancement at T2-weighted imaging were classed as HCCs.
To assess the statistical significance of the differences be-
tween the reading sessions, the McNemar test was used.
Quantitative Analysis
The degree of enhancement of the liver, tumors, and the
portal vein was calculated from signal intensity measure-
ments before and after intravenous injection of ferumox-
ides. For a lesion and for normal liver parenchyma, opera-
tor-defined region-of-interest (ROI) SI measurements were
obtained directly from the monitor. During the various
imaging sequences, care was taken to place the ROI for the
liver or portal vein in the same area, and for lesions with
necrotic areas, care was taken to measure SI only in solid
portions of the tumor. Whenever possible, an ROI of at
least 35 mm
2 was used; similar regions of interest were
used for unenhanced and ferumoxides-enhanced images.
For each image, background noise was measured ventral to
the liver outside the patient along the direction of the
phase-encoding gradient and included any ghosting arti-
facts that might have been propagated over the images.
For each sequence, signal-to-noise ratios (SNRs) for lesions
and liver were calculated using the following formula: SNR
= SI / SD, where SI is the signal intensity of the lesion or
liver parenchyma and SD is the standard deviation of
background noise. In addition, contrast-to-noise ratios
(CNRs) for lesion-to-liver and portal vein-to-liver were
computed for each sequence as follows: CNRlesion = (SI
lesion  SI liver) / SD, and CNRPV = (SI portal vein  SI
liver) / SD. These values were negative for hypointense le-
sions and positive for hyperintense lesions.
Statistical Analysis
One-way analysis of variance with pair-wise comparisons
was used to determine the statistical significance of the dif-
ferences between the ferumoxides-enhanced CNRs of each
type of tumor, as seen at T1-weighted FLASH imaging.
The post hoc Tukey test was used to determine which dif-
ferences were statistically significant, indicated by a p val-
ue of less than 0.05.
RESULTS
Qualitative Analysis
Before ferumoxides administration, T1-weighted FLASH
imaging showed that 61 of 70 lesions were hypointense
relative to the liver. Seven HCCs were slightly hyperin-
tense and two were isointense.
For each type of lesion, ferumoxides-enhanced T1-
weighted double-echo GRE images obtained during the
distributional phase demonstrated some degree of charac-
teristic enhancement. All 13 hemangiomas showed positive
enhancement at T1-weighted in- and out-of-phase GRE
imaging (Fig. 1). Intrahepatic vessels were also hyperin-
tense to the liver, with a degree of intensity similar to that
demonstrated by hemangiomas. In all of these, a slight de-
gree of signal intensity drop was noted, though for
metastatic tumors, HCCs and cysts, this was not the case.
Ferumoxides-enhanced T1-weighted double-echo imaging
revealed no enhancement of cystic lesions, though at distri-
butional-phase T1-weighted in- and out-of-phase imaging,
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(75%) and two of three cholangiocarcinomas (67%) (Figs.
2, 3). In addition, T1-weighted dual-echo imaging of HCCs
revealed slight enhancement in 24 lesions (80%), ring en-
hancement in two (6.7%), and no noticeable enhancement
in four (13.3%).
In terms of the relative signal intensity of focal liver le-
sions observed at T1-weighted double-echo GRE imaging,
out-of-phase images obtained using minimum echo time
better differentiated hemangiomas from other tumors than
did in-phase images (Table 1). Distributional-phase T1-
weighted out-of-phase imaging showed that no heman-
gioma was hypointense, but 11 of 12 metastatic lesions
(92%) and three cholangiocarcinomas (100%) were (Table
1). This same modality showed that 19 of 30 HCCs (63%)
Lee et al.
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Fig. 1. Liver hemangioma in a 67-year-old woman.
A. Precontrast T1-weighted in-phase gradient-echo image depicts a round hypointense lesion (arrow) in the right lobe of the liver.
B. Precontrast T2-weighted turbo spin-echo image shows a hyperintense lesion (arrow) in the liver.
C. Ferumoxides-enhanced T1-weighted in-phase gradient- echo image obtained during the distributional phase demonstrates positive
enhancement of the lesion (arrow), similar to that of the intrahepatic portal vein (open arrow). Note positive enhancement of the abdomi-
nal aorta (arrowhead).
D. Ferumoxides-enhanced T2-weighted turbo-spin echo image shows reduced intensity of the lesion (arrow) compared to precontrast
image (A).
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Table 1. Relative Signal Intensity of Focal Liver Lesions in
Ferumoxides-Enhanced T1-weighted Dual Echo
Sequence
Relative SI Mets HCC HMG CCC Cyst
T1W-IP
Hyperintense 2 13 13 1
Isointense 3 10 6
Hypointense 7 7 2 9
T1W-OP
Hyperintense 9 11
Isointense 1 2 2 3
Hypointense 10 19 3 12
Note. SI=signal intensity, Mets=metastases, HCC=hepatocellular
carcinoma, HMG=hemangioma, CCC=cholangiocarcinoma, T1W=T1-
weighted, IP=in-phase gradient-echo imaging using 4.2 ms echo time,
OP=out-of-phase gradient-echo imaging using 2.1 ms echo timewere hypointense, but nine HCCs seen as hyperintense at
precontrast T1-weighted imaging were also seen as hyper-
intense on all ferumoxides-enhanced T1-weighted out-of-
phase images because liver parenchyma showed a signal
decrease after the infusion of ferumoxides (Fig. 4) (Table
1).
Quantitative Analysis
A summary of the mean signal-to-noise ratios of liver le-
sions, liver parenchyma, and the portal vein, as seen at T1-
weighted imaging before and after ferumoxides enhance-
ment, is shown in Table 2. The enhancement of heman-
giomas was most marked, followed by that of HCCs,
cholangiocarcinomas, and metastases. The degree of en-
hancement of HCCs or adenocarcinomas revealed by T1-
weighted postcontrast imaging was considerably lower
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Fig. 2. Liver metastasis in a 67-year-old woman with gastric cancer. 
A. Precontrast T2-weighted turbo spin-echo image shows a hyperintense nodule (arrow) in the right lobe of the liver.
B. Postcontrast T1-weighted out-of-phase image demonstrates rim enhancement (arrow) of the peripheral portion of the lesion, which is
hypointense to the liver. Note positive enhancement of the intrahepatic portal vein (small arrowheads) and aorta (arrowhead).
C. Postcontrast T1-weighted in-phase image shows that the lesion (arrow) has become hyperintense to the liver.
D. Postcontrast T2 -weighted gradient-echo image obtained during the accumulation phase demonstrates markedly improved lesion (ar-
row)-to-liver contrast compared to precontrast T2-weighted image.
CD
AB
Table 2. Changes in Signal-to-Noise Ratio of Focal Liver
Lesions, Liver, and Portal Vein Before and After
Administration of Ferumoxides
T1-weighted T1-weighted
In-Phase GRE Opposed-Phase GRE
Precontrast Postcontrast Precontrast Postcontrast
HCC 24.6 90 25.6 70 25.6 12 31.0 80
Mets 22.6 10 20.8 80 24.3 20 23.3 60
HMG 16.2 14 33.7 36 16.6 13 34.3 24
Cysts 16.1 11 15.1 80 250. 22 19.3 16
CCC 23.6 30 24.9 70 28.9 60 30.1 60
Liver 27.7 70 22.1 60 30.1 10 31.7 80
Portal vein 18.2 40 41.5 13 18.3 60 47.1 11
Note. HCC=hepatocellular carcinoma, Mets=metastases, HMG
=hemangioma, CCC=cholangiocarcinoma, PRE=precontrast, POST=
postcontrast, T1W IP=T1-weighted in-phase gradient-echo imaging using
4.2 ms echo time, OP=out-of-phase gradient echo imaging using 2.1 ms
echo time, GRE=gradient-echo imagingthan that of hemangiomas (p < .05). At T2-weighted post-
contrast imaging, the signal of hemangiomas decreased
slightly. 
Figure 5 and Table 3 show CNRs for various tumors at
T1-weighted sequences before and after ferumoxides ad-
ministration. At distributional-phase T1-weighted imaging,
hemangiomas exhibited the greatest CNRs relative to sur-
rounding liver, and also the greatest lesion-to-portal vein
CNRs (Table 4). A statistically significant difference was
noted between the CNRs of hemangiomas and metastases
(p < .05) and between those of hemangiomas and HCCs (p
< .05).
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Fig. 3. Surgically-proven cholangiocarcinoma in segment 5 of the
liver.
A. Precontrast T2-weighted turbo spin-echo image shows a hetero-
geneously hyperintense lesion (arrows) with mild capsular retrac-
tion in the right lobe of the liver (arrowhead).
B. Precontrast T1-weighted in-phase gradient-echo image depicts
a hypointense mass (arrow).
C. On this T1-weighted out-of-phase gradient-echo image obtained
after the administration of ferumoxides, the lesion shows peripheral
rim enhancement (arrows).
D. T1-weighted in-phase gradient-echo image obtained after the
administration of ferumoxides shows that the lesion (arrows) has
become slightly hyperintense to the liver.
E. On this T2 -weighted gradient-echo image obtained after the
administration of ferumoxides, the lesion (arrow) has become very
hyperintense to the liver. Note that this accumulation phase image
provides excellent contrast and lesion conspicuity.
ELesion Characterization on Postcontrast Images
The accuracy of each reading set is shown in Table 5. Set
B (combined distributional phase and accumulation phase
imaging) shows that all hemangiomas and cysts were cor-
rectly diagnosed. The characterization of focal liver lesions
as benign or malignant was better evaluated by set B
(overall accuracy=88%) than set A (overall accuracy=75
%) (p = .07). When a specific diagnosis was requested, the
accuracy of set B decreased to 82%, but was still better
than that of set A (p < .05). The additional information
provided by ferumoxides-enhanced T1-weighted images
obtained during the distributional phase has been shown to
be useful for further characterization of focal liver lesions.
DISCUSSION
The use of ferumoxides in MR imaging of the liver has
been the focus of many investigations, and it is now widely
accepted that ferumoxides increase the detection rate of
focal liver lesions at T2-weighted imaging (4 6). Several
authors, however, have encountered difficulties in differ-
entiating benign from malignant lesions at ferumoxides-en-
hanced MR imaging (11, 19), and until recently, only a
small number of reports focused on lesion characterization
under this circumstance (8 13). Furthermore, in most pre-
vious studies, investigators employed a T2-weighted se-
Distributional-Phase T1-Weighted Imaging of Superparamagnetic Iron Oxide-Enhanced MR in Focal Liver Lesions
Korean J Radiol 4(1), March 2003 15
Fig. 4. A 65-year-old man with biopsy-proven hepatocellular carcinoma in the right lobe of the liver.
A. Precontrast T1-weighted out-of-phase gradient-echo image depicts a hyperintense tumor (arrow) with a hypointense capsule in the
right lobe of the liver.
B. Postcontrast T1-weighted out-of-phase gradient-echo image obtained during the distributional phase shows that the lesion (arrow) is
hyperintense compared to the liver, but much less hyperintense than the branches of the intrahepatic portal vein (open arrows).
C. Postcontrast T1 in-phase gradient-echo image obtained during the distributional phase shows that the lesion (arrow) has become
more hyperintense than the liver but is still less hyperintense than the branches of the portal vein (open arrows). Note the presence of
multiple hypointense regenerating nodules in the liver parenchyma.
D. Postcontrast T2 -weighted gradient echo image shows markedly improved lesion (arrow)-to-liver contrast due to the substantially de-
creased liver parenchymal signal.
CD
ABquence to characterize focal liver lesions, using the signal
loss related to iron particle uptake of Kupffer cells located
in benign liver lesions such as focal nodular hyperplasia,
adenoma and hemangioma (8 11). However, in a clinical
setting, the signal change of focal liver lesions makes it dif-
ficult to distinguish metastases from hemangioma on T2-
weighted images because metastatic lesions are hyperin-
tense. This can be a more serious problem when small le-
sions of less than two centimeters are being imaged.
Several authors have recently described T1-weighted GRE
images obtained 30 minutes to 1 hour after the administra-
tion of ferumoxides, noting that they were valuable for
characterizing focal liver lesions observed at SPIO-en-
hanced MR imaging (8 10, 12, 13).
In this study, T1-weighted imaging began within ten min-
utes of the end of contrast infusion, a rationale based on
the results of previous reports regarding the plasma half-
life of ferumoxides (19, 20). The most noticeable findings
observed in this study were that T1-weighted out-of-phase
imaging using minimum echo-time best differentiated he-
mangiomas from other tumors. As in the findings of previ-
ous studies regarding lesion characterization with ferumox-
ides-enhanced MR imaging (9, 10), hemangiomas showed
the highest degree of signal enhancement at T1-weighted
imaging. During the distributional phase, only heman-
giomas showed a positive mean lesion-to-liver CNR; for
other lesions this was negative. Only HCCs showing hy-
perintensity at precontrast T1-weighted imaging demon-
strated hyperintensity at postcontrast T1-weighted out-of-
phase imaging using 2.1 ms echo time, but due to the T1
effects of circulating iron particles, the degree of hyperin-
tensity was much lower than that of the portal vein. These
results suggest that to improve the efficacy of ferumoxides-
enhanced MR imaging for the differentiation of hepatic he-
mangiomas and malignant liver lesions, T1-weighted GRE
imaging using minimum echo-time and performed during
the distributional phase, thus demonstrating the T1-effect
of circulating iron particles in the blood, should be added
to T2-weighted and T2*-weighted imaging.
Quantitative analysis performed in this study showed
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Table 3. Contrast-to-Noise Ratio of Focal Hepatic Lesions at
each Ferumoxides-Enhanced MR Imaging Sequ-
ence
T1W   IP T1W   OP T2W   TSE T2*W   GRE
(Mean S.D.)(Mean S.D.)(Mean S.D.)(Mean S.D.)
HCC PRE 3.1 7.5 5.0 10.5 5.5 6.3 0.74 12.5
POST 3.5 4.2 0.6 6.8 12.0 8.4 26.25 12.0
Mets PRE 10.2 3.1 14.7 7.0 10.0 3.5 5.90 8.5
POST 6.6 1.1 9.7 7 21.2 3.3 40.20 12.6
HMG PRE 8.6 5.5 11.8 7.9 18.4 4.6 08.30 12.4
POST 15.6 19.4 8.2 6.0 17.3 4.6 37.12 20.4
CCC PRE 9.4 2.5 12.3 6.0 5.1 3.5 03.00 3.3
POST 3.3 5.4 14.0 7.1 16.5 3.3 47.20 21
Cyst PRE 16.4 3.8 13.5 1.7 43.2 10.5 13.60 4.3
POST 11.3 2.8 22.8 3.6 49.4 0.3 30.61 8.4
Note. HCC=hepatocellular carcinoma, Mets=metastases, HMG=he-
mangioma, CCC=cholangiocarcinoma, PRE=precontrast, POST=post-
contrast, T1W IP=T1-weighted in-phase gradient-echo imaging using 4.2
ms echo time, OP=out-of-phase gradient-echo imaging using 2.1 ms echo
time, TSE=turbo spin-echo, GRE=gradient-echo image
Table 5. Accuracy of Characterization of Detected Lesions
as Benign or Malignant, and of Diagnosis of Tumor
Type
Imaging Sets Characterization Diagnosis
Postcontrast T2WI & T2 WI 75% (55/73) 56% (41/73)
Combined postcontrast 88% (64 /73) 82% (60/73)
T1WI, T2WI, & T2 WI
Note. T1WI=T1-weighted imaging, T2WI=T2-weighted imaging, T2 WI
=T2 star-weighted imaging
Table 4. The Lesion to Portal Vein Contrast-to-Noise Ratio at
Ferumoxides-Enhanced T1-weighted FLASH Imag-
ing
T1W  OP T1W  IP
(Mean SD) (Mean SD)
HCC 15.2 12 14.1 11
Metastases 25.8 26 12.8 9
Hemangioma -1.1 2 1.4 2.4
Cholangiocarcinoma 25.3 19 12.6 14
Cyst 38.1 14 42.7 26
Note. T1W=T1-weighted, OP=out-of-phase fast low-angle shot using
2.1 ms echo time, IP=in-phase fast low-angle shot using 4.2 ms echo
time, HCC=hepatocellular carcinoma;  The differences between
hemangioma and other lesions were statistically significant.
Fig. 5. Lesion-to-liver contrast-to-noise ratio of focal hepatic le-
sions seen on T1-weighted in-phase and out-of-phase gradient-
echo images obtained during the distributional phase
HCC HMG Mets CCC Cyst
C
N
Rthat the lesion-to-liver CNRs of lesions seen at postcontrast
T1-weighted GRE imaging were relatively lower than
those observed in the previous studies of Nakayama et al.
(12) and Kim et al. (13). This is because during the distribu-
tional phase, the contrast uptake of Kupffer cells was small
and the liver parenchyma signal therefore decreased only
slightly. However, the lesion-to-liver CNRs of lesions seen
at T2*-weighted GRE imaging during the accumulation
phase of our study were similar to those observed in previ-
ous studies (Figs. 3, 4). Given that T1-weighted SPIO-en-
hanced MR imaging is useful for lesion characterization,
not lesion detection, obtaining T1-weighted images during
the distributional phase may, because of the presence of
circulating iron particles, be better for observing positive
enhancement of focal liver lesions.
Owing to the differences demonstrated by the hepatic tu-
mor enhancement profiles, most tumors (82%) could be
correctly characterized during the distributional phase of
T1- and T2-weighted imaging. Hemangiomas became hy-
perintense at postcontrast T1-weighted imaging, with a
characteristic drop in SI at postcontrast T2-weighted imag-
ing (8, 9). The enhancement pattern of hemangiomas seen
at ferumoxides- enhanced imaging is probably due to the
high volume of ferumoxide-laden blood present in the en-
larged vascular spaces of the lesion. Although HCCs
showed some enhancement at ferumoxides-enhanced T1-
weighted imaging, the degree of this was significantly low-
er than for hemangiomas (p < .05). All hypovascular tu-
mors, including metastases (n=12) and cholangiocarcino-
mas (n=3), showed only slight enhancement (n=4) or pe-
ripheral ring enhancement (n=11) at ferumoxides-en-
hanced T1-weighted imaging, but cysts showed no en-
hancement. These differences in the characteristics of T1-
weighted enhancement, combined with the characteristic
drop in SI for hemangiomas at T2-weighted postcontrast
imaging, may be of some value in the characterization of
these lesions.
It has been suggested that the presence of ring enhance-
ment following the administration of ferumoxides can help
characterize focal hepatic lesions (21) and also differentiate
benign from malignant liver lesions. In our study, most hy-
povascular malignant tumors, such as metastases and
cholangiocarcinomas (11/15, 73.3%), and a small number
of HCCs (3/30, 10%) demonstrated ring enhancement; he-
mangiomas or cysts, on the other hand, did not. We thus
assume that this sign also helps to differentiate hypovascu-
lar malignant tumor lesions from other tumors seen at feru-
moxides-enhanced T1-weighted imaging.
In ferumoxides-enhanced MR imaging, the fact that the
infusion time of the contrast medium is long has given rise
to controversy as to whether, for this reason, precontrast
imaging is needed. Kim et al. (13) have demonstrated that
at T1-weighted minimum-TE GRE imaging, all FNHs and
hemangiomas, but no HCCs and only 3% of metastases,
were hyperintense, results which suggest that from a clini-
cal standpoint, the need to obtain precontrast images is not
great. In our study, however, the signal intensity of HCCs
at unenhanced T1-weighted imaging varied: approximately
37% were hyper- or iso-intense compared to the liver at
postcontrast T1-weighted out-of-phase GRE imaging. The
observed reduction in the signal intensity of liver
parenchyma after the infusion of ferumoxides is almost al-
ways greater than that of HCCs; a lesion which is hyperin-
tense at precontrast T1-weighted imaging can become
more hyperintense and harder to differentiate from he-
mangioma. Furthermore, although it may save time, the
elimination of unenhanced imaging can be detrimental to
the characterization of hepatocellular tumors such as FNH,
adenoma, and well-differentiated HCC, for which SI rela-
tionships with normal unenhanced liver are routinely ex-
amined in lesion characterization. For this reason, it would
seem prudent to retain the use of unenhanced scanning,
though to clarify this issue, further studies may be neces-
sary.
Our study suffers a number of limitations. First, although
the study group was large, the relative number of benign
lesions was small, thereby reflecting the prevalence of
some less common lesions. Second, the presence of some
HCCs and some metastases was not pathologically proven.
Instead, typical clinical and laboratory findings in combina-
tion with typical imaging findings of other imaging modali-
ties were used as the diagnostic criteria. Last, cases of nei-
ther focal nodular hyperplasia nor adenoma, which can
cause difficulties in differentiating focal liver lesions, were
included in this study.
In conclusion, the use of T1-weighted double-echo
FLASH imaging, performed soon after the infusion of feru-
moxides, improved the differentiation of hepatic heman-
giomas from malignant liver lesions and may help increase
the accuracy with which malignant lesions are detected.
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